Ontario Teachers Pension Plan Board Makes New $274,000 Investment in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Ontario Teachers Pension Plan Board bought a new position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 1,833 shares of the biopharmaceutical company’s stock, valued at approximately $274,000.

Other large investors have also bought and sold shares of the company. Allspring Global Investments Holdings LLC increased its position in Alnylam Pharmaceuticals by 572.0% in the first quarter. Allspring Global Investments Holdings LLC now owns 168 shares of the biopharmaceutical company’s stock worth $25,000 after buying an additional 143 shares during the last quarter. Quent Capital LLC raised its position in Alnylam Pharmaceuticals by 246.0% during the fourth quarter. Quent Capital LLC now owns 173 shares of the biopharmaceutical company’s stock valued at $33,000 after purchasing an additional 123 shares in the last quarter. Robeco Institutional Asset Management B.V. increased its holdings in shares of Alnylam Pharmaceuticals by 155.7% in the fourth quarter. Robeco Institutional Asset Management B.V. now owns 20,549 shares of the biopharmaceutical company’s stock worth $39,000 after buying an additional 12,513 shares during the period. GAMMA Investing LLC purchased a new position in Alnylam Pharmaceuticals during the 4th quarter valued at about $52,000. Finally, V Square Quantitative Management LLC purchased a new position in Alnylam Pharmaceuticals during the 4th quarter valued at about $52,000. 92.97% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of analysts have recently commented on ALNY shares. Wells Fargo & Company boosted their price target on Alnylam Pharmaceuticals from $161.00 to $207.00 and gave the stock an “equal weight” rating in a research report on Tuesday, June 25th. Chardan Capital restated a “buy” rating and set a $225.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Friday, May 3rd. HC Wainwright reiterated a “buy” rating and issued a $400.00 price target on shares of Alnylam Pharmaceuticals in a research report on Monday, June 24th. Needham & Company LLC lifted their price target on shares of Alnylam Pharmaceuticals from $200.00 to $275.00 and gave the company a “buy” rating in a research note on Monday, June 24th. Finally, Barclays boosted their price objective on shares of Alnylam Pharmaceuticals from $236.00 to $291.00 and gave the stock an “overweight” rating in a research note on Tuesday, June 25th. Eight equities research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the stock. Based on data from MarketBeat.com, Alnylam Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus target price of $256.73.

Alnylam Pharmaceuticals Price Performance

Shares of ALNY stock traded up $2.16 on Tuesday, hitting $237.75. The stock had a trading volume of 68,381 shares, compared to its average volume of 883,560. Alnylam Pharmaceuticals, Inc. has a 52-week low of $141.98 and a 52-week high of $263.73. The stock’s 50 day moving average is $192.03 and its 200-day moving average is $171.27.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its earnings results on Thursday, May 2nd. The biopharmaceutical company reported ($0.52) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.75) by $0.23. The business had revenue of $494.33 million for the quarter, compared to analyst estimates of $428.01 million. The firm’s revenue for the quarter was up 54.8% on a year-over-year basis. During the same period last year, the company posted ($1.40) earnings per share. Equities research analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -3.99 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, Director Amy W. Schulman sold 21,700 shares of the stock in a transaction dated Wednesday, May 29th. The shares were sold at an average price of $148.60, for a total value of $3,224,620.00. Following the sale, the director now owns 8,436 shares of the company’s stock, valued at approximately $1,253,589.60. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. In related news, Director Amy W. Schulman sold 21,700 shares of the stock in a transaction dated Wednesday, May 29th. The shares were sold at an average price of $148.60, for a total value of $3,224,620.00. Following the sale, the director now owns 8,436 shares of the company’s stock, valued at approximately $1,253,589.60. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director David E. I. Pyott sold 32,450 shares of the stock in a transaction dated Monday, June 24th. The shares were sold at an average price of $220.69, for a total transaction of $7,161,390.50. Following the completion of the transaction, the director now owns 136 shares of the company’s stock, valued at approximately $30,013.84. The disclosure for this sale can be found here. Over the last three months, insiders have sold 74,450 shares of company stock valued at $15,287,984. Company insiders own 1.50% of the company’s stock.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.